Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Q3 2026 earnings

Reported October 29, 2026 · Before market open

Revenue$356.0MBeat by $26.7M
EPS$1.32Beat by $0.26
Revenue estimate$329.4M
EPS estimate$1.06
“In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda. Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda. I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible. I am confident in Supernus' future and its ability to build on this strong foundation for people living with central nervous system diseases and to create long-term value for shareholders.”
Joe Ciaffoni

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$356.0M+13.4%
Gross profit$305.0M+32.6%
Operating income$180.0M+319%
Net income$137.0M+226%
EPS (diluted)$1.12+239%

Balance sheet

See full
Cash & equivalents$305.0M-31.5%
Total debt$501.0M+40.7%
Total equity-$60.0M+71.0%
Total assets$1.3B-5.9%

Cash flow

See full
Operating cash flow$97.0M—
CapEx$14.0M-30.0%
Free cash flow$83.0M—

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$4.16B+14.5%
Enterprise value$4.36B+22.9%
P/E9.3×-19.2×
P/S3×0.0×

Profitability

See full
Gross margin85%+4.5pp
Operating margin40.6%+21.4pp
Net margin32.8%+21.9pp
FCF margin15.8%—

Returns & leverage

See full
Current ratio0.6×-0.3×

Segments

By product

See full
SUBLOCADE$267.0M+21.9%
Sublingual & other$53.0M+3.9%
PERSERIS$2.0M-66.7%

By segment

See full
Reportable Segment$356.0M+13.4%

By geography

See full
Rest of World$48.0M+2.1%

FAQ

When did Indivior Pharmaceuticals, Inc. report Q3 2026 earnings?
Indivior Pharmaceuticals, Inc. (INDV) reported Q3 2026 earnings on October 29, 2026 before market open.
What were Indivior Pharmaceuticals, Inc.'s Q3 2026 revenue and EPS?
Indivior Pharmaceuticals, Inc. reported revenue of $356.0M and eps of $1.32 for Q3 2026.
Did Indivior Pharmaceuticals, Inc. beat estimates in Q3 2026?
Revenue beat the consensus estimate of $329.4M by $26.7M. EPS beat the consensus estimate of $1.06 by $0.26.
How did Indivior Pharmaceuticals, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.4% from $314.0M a year earlier and eps grew 83.3% from $0.72.
Where can I find Indivior Pharmaceuticals, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-436953) and the 10-Q periodic report (0001628280-26-068013) directly on SEC EDGAR. The filing index links above go to sec.gov.